Small-Cap Biotech Stocks Are Having a Rough Year, But That Could Change in a Heartbeat

While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their small-cap rivals have been sinking. But some analysts say the latest figures suggest a bargain in the sector.